Prion-like Mechanism in Amyotrophic Lateral Sclerosis: are Protein Aggregates the Key?

ALS is a fatal adult-onset motor neuron disease. Motor neurons in the cortex, brain stem and spinal cord gradually degenerate in ALS patients, and most ALS patients die within 3~5 years of disease onset due to respiratory failure. The major pathological hallmark of ALS is abnormal accumulation of protein inclusions containing TDP-43, FUS or SOD1 protein. Moreover, the focality of clinical onset and regional spreading of neurodegeneration are typical features of ALS. These clinical data indicate that neurodegeneration in ALS is an orderly propagating process, which seems to share the signature of a seeded self-propagation with pathogenic prion proteins. In vitro and cell line experimental evidence suggests that SOD1, TDP-43 and FUS form insoluble fibrillar aggregates. Notably, these protein fibrillar aggregates can act as seeds to trigger the aggregation of native counterparts. Collectively, a self-propagation mechanism similar to prion replication and spreading may underlie the pathology of ALS. In this review, we will briefly summarize recent evidence to support the prion-like properties of major ALS-associated proteins and discuss the possible therapeutic strategies for ALS based on a prion-like mechanism.

[1]  D. Dinsdale,et al.  Sustained translational repression by eIF2α-P mediates prion neurodegeneration , 2012, Nature.

[2]  D. Mann,et al.  Prion-like properties of pathological TDP-43 aggregates from diseased brains. , 2013, Cell reports.

[3]  Christian Münch,et al.  Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells , 2011, Proceedings of the National Academy of Sciences.

[4]  A. Verma Protein aggregates and regional disease spread in ALS is reminiscent of prion-like pathogenesis. , 2013, Neurology India.

[5]  B. Maddison,et al.  Prion transmission , 2010, Prion.

[6]  J. Collinge,et al.  Superoxide Dismutase 1 and tgSOD1G93A Mouse Spinal Cord Seed Fibrils, Suggesting a Propagative Cell Death Mechanism in Amyotrophic Lateral Sclerosis , 2010, PloS one.

[7]  Chen Wang,et al.  An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity , 2011, Nature Structural &Molecular Biology.

[8]  Yuxin Fan,et al.  Implications of ALS focality , 2007, Neurology.

[9]  A. Gitler,et al.  TDP-43 Is Intrinsically Aggregation-prone, and Amyotrophic Lateral Sclerosis-linked Mutations Accelerate Aggregation and Increase Toxicity* , 2009, The Journal of Biological Chemistry.

[10]  R. Baloh TDP‐43: the relationship between protein aggregation and neurodegeneration in amyotrophic lateral sclerosis and frontotemporal lobar degeneration , 2011, The FEBS journal.

[11]  L. Piedrafita,et al.  Accumulation of Misfolded SOD1 in Dorsal Root Ganglion Degenerating Proprioceptive Sensory Neurons of Transgenic Mice with Amyotrophic Lateral Sclerosis , 2014, BioMed research international.

[12]  A. Tiwari,et al.  Mutant SOD1 Instability: Implications for Toxicity in Amyotrophic Lateral Sclerosis , 2006, Neurodegenerative Diseases.

[13]  J. Trojanowski,et al.  Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration , 2011, Nature Reviews Neuroscience.

[14]  J. Trojanowski,et al.  Pathological TDP‐43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations , 2007, Annals of neurology.

[15]  L. Bruijn,et al.  Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. , 1998, Science.

[16]  S. Thellung,et al.  Role of Prion Protein Aggregation in Neurotoxicity , 2012, International journal of molecular sciences.

[17]  N. Nukina,et al.  Intranuclear Aggregation of Mutant FUS/TLS as a Molecular Pathomechanism of Amyotrophic Lateral Sclerosis* , 2013, The Journal of Biological Chemistry.

[18]  P. Fischer,et al.  Oral Treatment Targeting the Unfolded Protein Response Prevents Neurodegeneration and Clinical Disease in Prion-Infected Mice , 2013, Science Translational Medicine.

[19]  J. Rothstein,et al.  Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies , 2014, Trends in Neurosciences.

[20]  C. van Broeckhoven,et al.  Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD–ALS spectrum disorders , 2013, Human molecular genetics.

[21]  J. Julien,et al.  Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS , 2010, Journal of neurochemistry.

[22]  S. Napper,et al.  Evidence for Prion-Like Mechanisms in Several Neurodegenerative Diseases: Potential Implications for Immunotherapy , 2013, Clinical & developmental immunology.

[23]  Ewout J. N. Groen,et al.  Protein aggregation in amyotrophic lateral sclerosis , 2013, Acta Neuropathologica.

[24]  J. Mendell,et al.  Astrocytes from Familial and Sporadic ALS Patients are Toxic to Motor Neurons , 2011, Nature Biotechnology.

[25]  M. E. Kabir,et al.  Implications of prion adaptation and evolution paradigm for human neurodegenerative diseases , 2014, Prion.

[26]  D. Cleveland,et al.  Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria , 2008, Proceedings of the National Academy of Sciences.

[27]  A. Bertolotti,et al.  Self-propagation and transmission of misfolded mutant SOD1: Prion or prion-like phenomenon? , 2011, Cell cycle.

[28]  D. A. Bosco,et al.  An emerging role for misfolded wild-type SOD1 in sporadic ALS pathogenesis , 2013, Front. Cell. Neurosci..

[29]  Kenji Nakashima,et al.  New consensus research on neuropathological aspects of familial amyotrophic lateral sclerosis with superoxide dismutase 1 (SOD1) gene mutations: Inclusions containing SOD1 in neurons and astrocytes , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[30]  S. Pozzi,et al.  Mutant Copper-Zinc Superoxide Dismutase (SOD1) Induces Protein Secretion Pathway Alterations and Exosome Release in Astrocytes , 2013, The Journal of Biological Chemistry.

[31]  C. Svendsen,et al.  The past, present and future of stem cell clinical trials for ALS , 2014, Experimental Neurology.

[32]  C. B. Kunst,et al.  Effect of genetic background on phenotype variability in transgenic mouse models of amyotrophic lateral sclerosis: A window of opportunity in the search for genetic modifiers , 2011, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[33]  A. Gitler,et al.  RNA-binding proteins with prion-like domains in ALS and FTLD-U , 2011, Prion.

[34]  C. Hetz,et al.  ER Dysfunction and Protein Folding Stress in ALS , 2013, International journal of cell biology.

[35]  P. Drapeau,et al.  Fishing for causes and cures of motor neuron disorders , 2014, Disease Models & Mechanisms.

[36]  Adriano Chiò,et al.  State of play in amyotrophic lateral sclerosis genetics , 2013, Nature Neuroscience.

[37]  David S Wishart,et al.  Intermolecular transmission of superoxide dismutase 1 misfolding in living cells , 2011, Proceedings of the National Academy of Sciences.

[38]  D. Cleveland,et al.  The Seeds of Neurodegeneration: Prion-like Spreading in ALS , 2011, Cell.

[39]  T. O’Halloran,et al.  Complete Loss of Post-translational Modifications Triggers Fibrillar Aggregation of SOD1 in the Familial Form of Amyotrophic Lateral Sclerosis* , 2008, Journal of Biological Chemistry.

[40]  P. Andersen,et al.  Misfolded superoxide dismutase‐1 in CSF from amyotrophic lateral sclerosis patients , 2011, Journal of neurochemistry.

[41]  N. Nukina,et al.  A Seeding Reaction Recapitulates Intracellular Formation of Sarkosyl-insoluble Transactivation Response Element (TAR) DNA-binding Protein-43 Inclusions*♦ , 2011, The Journal of Biological Chemistry.

[42]  Jimin Pei,et al.  Cell-free Formation of RNA Granules: Low Complexity Sequence Domains Form Dynamic Fibers within Hydrogels , 2012, Cell.

[43]  J. Trojanowski,et al.  Therapeutic modulation of eIF2α-phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models , 2013, Nature Genetics.